Pathological classification and surgical prognosis of idiopathic hyperaldosteronism

Abstract

Abstract: Objective There are a few reports on surgical treatment of idiopathic hyperaldosteronism (IHA),pathological profile and prognosis. The clinical and pathological characteristics and prognosis of 23 patients with IHA were retrospectively analyzed in order to support potential improvement of diagnosis and treatment outcome. Methods Clinical characteristics of 23 patients with IHA were analyzed retrospectively. HE staining and CYP11B2 immunostaining were performed for pathological microsocopic observation. Pathological features and surgical prognosis were analyzed. Results All samples were categorized as nonclassic pathology, including 12 cases with multiple aldosterone-producing nodules,10 cases with multiple or single aldosterone-producing micronodules. Only one case had aldosterone-producing diffuse hyperplasia. Unilateral adrenal resection was performed in all patients. Postoperatively, blood pressure and serum potassium recovered to normal range in 6 patients with a cure rate 26%. Blood pressure decreased but did not return to normal in 17 patients (improve rate 74%). Compared with the improved group, patients in the cured group had a lower pre-operative blood pressure (P＜0.05). Conclusions Multiple functional nodules and micronodules are the main types in adrenal pathology of IHA. Unilateral adrenal resections probably bring clinical benefits in these patients.

Key words: idiopathic hyperaldosteronism, pathological classification, surgical prognosis

CLC Number:

R586.9

WANG Hui-ping, CUI Yun-ying, MA Xiao-sen, WEN Jin, REN Wei-dong, TONG An-li. Pathological classification and surgical prognosis of idiopathic hyperaldosteronism[J]. Basic & Clinical Medicine, 2021, 41(10): 1481-1485.

References

[1]Kline GA, Prebtani APH, Leung AA, et al. Primary aldosteronism: a common cause of resistant hypertension[J]. Cmaj, 2017, 189: e773-e778.
[2]Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives[J]. J Intern Med, 2019, 285: 126-148.
[3]Funder JW, Carey RM, Mantero F, et al. The Manage-ment of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2016, 101: 1889-1916.
[4]Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism[J]. Surgery, 2004, 136: 1227-1235.
[5]Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery[J]. Ann Intern Med, 2001, 135: 258-261.
[6]Nwariaku FE, Miller BS, Auchus R, et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome[J]. Arch Surg, 2006, 141: 497-502.
[7]Omata K, Satoh F, Morimoto R, et al. Cellular and genetic causes of idiopathic hyperaldosteronism[J]. Hypertension, 2018, 72: 874-880.
[8]Meyer LS, Wang X, Sušnik E, et al. Immunohistopathology and steroid profiles associated with biochemical outcomes after adrenalectomy for unilateral primary aldosteronism[J]. Hypertension, 2018, 72: 650-657.
[9]Dekkers T, Prejbisz A, Kool LJS, et al. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial[J]. Lancet Diabetes Endocrinol, 2016, 4: 739-746.
[10]Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort[J]. Lancet Diabetes Endocrinol, 2017, 5: 689-699.